Connect with us


Cannabis firm CiiTECH raises £2.1 million ahead of stock exchange debut

The company is pursuing a number of “new opportunities”.



The company plans to list on the London Stock Exchange

Science-led cannabis company CiiTECH has successfully completed a £2.1 million capital raise as it prepares to go public.

The company announced on Tuesday 7 July that it has successfully raised £2.1 million through the issue of Convertible Loan Notes ahead of a reverse takeover.

Investors include FastForward Innovations Ltd and others, including professional family offices and ultra-high-net-worth individuals.

The capital will be used to fund CiiTECH’s marketing strategy, invest in new talent, build essential operational infrastructure to support future growth and finance the planned reverse takeover of the company.

The company intends to apply for the admission of its ordinary share capital as enlarged by the acquisition of CiiTECH to the Standard Segment of the Official List and to trading on the Main Market of the London Stock Exchange (LSE).

CiiTECH has generated over £7 million in revenue since its inception in 2017, and has built a portfolio of consumer CBD brands, including Provocan, Impact Sports and Hugg.

CiiTECH CEO, Clifton Flack with world-leading cannabis scientist Raphael Mechoulam

Clifton Flack, founder and CEO of CiiTECH said the company is pursuing a number of ‘new opportunities’, and would soon be rolling out its cannabis healthcare education platform.

He commented: “We are pleased with the strong interest in this fundraise, which enables us to continue implementing our aggressive growth strategy.

“We are grateful to all investors supporting our fundraising efforts and look forward to completing the RTO of FPP and becoming a listed business.

“We would like to thank Chrystal Capital Partners LLP, who acted as our exclusive financial adviser, for playing a critical role in not only raising the capital but also finding an optimal capital markets partner in Fragrant Prosperity.

“Our science-led approach focuses on identifying clear product needs in our chosen territories and then sourcing solutions for these new markets. We are pursuing a number of exciting opportunities, including rolling out our CBD wellness brand portfolio in Israel and South Africa, whilst implementing our medical cannabis strategy through a number of global supply chain partnerships.

“Our consumer cannabis brands are soon to be supported with the launch of our ‘Cannabis Healthcare Education Course’ that is being rolled out as part of our localised and segmented B2B marketing strategy.”

Chrystal Capital Partners LLP, Europe’s leading cannabis corporate finance and investment house acted as exclusive financial adviser.

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.